Physiol. Genomics Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 31: 402-409, 2007. First published August 14, 2007; doi:10.1152/physiolgenomics.00104.2007
1094-8341/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
31/3/402    most recent
00104.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ardigo, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ardigo, D.
Received 7 May 2007; accepted in final form 7 August 2007.
Physiological Genomics 31:402-409 (2007)
1094-8341/06 $8.00 © 2007 American Physiological Society

Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease

Diego Ardigo 1,2,*, Themistocles L. Assimes 1,*, Stephen P. Fortmann 3, Alan S. Go 4,5, Mark Hlatky 1, Evangelos Hytopoulos 6, Carlos Iribarren 4, Philip S. Tsao 1, Raymond Tabibiazar 1,6, Thomas Quertermous 1 for the ADVANCE Investigators

1 Division of Cardiovascular Medicine, Stanford University, Stanford, California
2 Department of Internal Medicine and Biomedical Sciences, Parma University, Parma, Italy
3 Stanford Prevention Research Center, Stanford University, Stanford
4 Division of Research, Kaiser Permanente of Northern California, Oakland
5 Department of Epidemiology, Biostatistics, & Medicine, University of California at San Francisco, San Francisco, California
6 Aviir, Incorporated, Palo Alto, California

Serum inflammatory markers correlate with outcome and response to therapy in subjects with cardiovascular disease. However, current individual markers lack specificity for the diagnosis of coronary artery disease (CAD). We hypothesize that a multimarker proteomic approach measuring serum levels of vascular derived inflammatory biomarkers could reveal a "signature of disease" that can serve as a highly accurate method to assess for the presence of coronary atherosclerosis. We simultaneously measured serum levels of seven chemokines [CXCL10 (IP-10), CCL11 (eotaxin), CCL3 (MIP1{alpha}), CCL2 (MCP1), CCL8 (MCP2), CCL7 (MCP3), and CCL13 (MCP4)] in 48 subjects with clinically significant CAD ("cases") and 44 controls from the ADVANCE Study. We applied three classification algorithms to identify the combination of variables that would best predict case-control status and assessed the diagnostic performance of these models with receiver operating characteristic (ROC) curves. The serum levels of six chemokines were significantly higher in cases compared with controls (P < 0.05). All three classification algorithms entered three chemokines in their final model, and only logistic regression selected clinical variables. Logistic regression produced the highest ROC of the three algorithms (AUC = 0.95; SE = 0.03), which was markedly better than the AUC for the logistic regression model of traditional risk factors of CAD without (AUC = 0.67; SE = 0.06) or with CRP (AUC = 0.68; SE = 0.06). A combination of serum levels of multiple chemokines identifies subjects with clinically significant atherosclerotic heart disease with a very high degree of accuracy. These results need to be replicated in larger cross-sectional studies and their prognostic value explored.

coronary artery disease; multimarker; biomarkers; atherosclerosis; protein microarray; proteomic; inflammation; chemokines




This article has been cited by other articles:


Home page
Eur Respir JHome page
M. Ruhwald, T. Bodmer, C. Maier, M. Jepsen, M. B. Haaland, J. Eugen-Olsen, P. Ravn, and on behalf of TBNET
Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis
Eur. Respir. J., December 1, 2008; 32(6): 1607 - 1615.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Aukrust, B. Halvorsen, A. Yndestad, T. Ueland, E. Oie, K. Otterdal, L. Gullestad, and J. K. Damas
Chemokines and Cardiovascular Risk
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1909 - 1919.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. A. Gleissner, P. von Hundelshausen, and K. Ley
Platelet Chemokines in Vascular Disease
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1920 - 1927.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.